Listed

Amneal Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2019

Filed with the SEC on Aug 5, 2019 and accepted by EDGAR at Aug 5, 2019, 16:39 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-04-01 to 2019-06-30$404.6mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2019-01-01 to 2019-06-30$850.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2019-04-01 to 2019-06-30$296.4mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2019-01-01 to 2019-06-30$606.1mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2019-04-01 to 2019-06-30$105.2mus-gaap:GrossProfit
Gross profit6 months2019-01-01 to 2019-06-30$188.3mus-gaap:GrossProfit
Research and development3 months2019-04-01 to 2019-06-30$48.0mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2019-01-01 to 2019-06-30$101.9mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2019-04-01 to 2019-06-30$67.3mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2019-01-01 to 2019-06-30$151.7mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2019-04-01 to 2019-06-30−$18.9mus-gaap:OperatingIncomeLoss
Operating income6 months2019-01-01 to 2019-06-30−$113.3mus-gaap:OperatingIncomeLoss
Income tax3 months2019-04-01 to 2019-06-30−$5.7mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2019-01-01 to 2019-06-30−$14.1mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-04-01 to 2019-06-30−$16.9mus-gaap:NetIncomeLoss
Net income6 months2019-01-01 to 2019-06-30−$64.8mus-gaap:NetIncomeLoss
Operating cash flow6 months2019-01-01 to 2019-06-30−$87.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2019-01-01 to 2019-06-30$29.6mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid6 months2019-01-01 to 2019-06-30$0us-gaap:PaymentsOfDividends
Cash and equivalentsAt period end2019-06-30$54.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-06-30$1.19bnus-gaap:AssetsCurrent
Total assetsAt period end2019-06-30$4.26bnus-gaap:Assets
Current liabilitiesAt period end2019-06-30$546.2mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2019-06-30$2.62bnus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2019-06-30$459.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001723128-19-000111. Last ingested by Listed: Nov 10, 2026, 02:45 ET. Listed shows no prices and gives no investment advice.